Exposure to nanoparticles during pregnancy is a public concern, because
nanoparticles may pass from the mother to the fetus across the placenta. The purpose of
this study was to determine the possible translocation pathway of gold nanoparticles
across the maternal–fetal barrier as well as the toxicity of intravenously administered
gold nanoparticles to the placenta and fetus. Pregnant ICR mice were intravenously
injected with 0.01% of 20- and 50-nm gold nanoparticle solutions on the 16th and 17th days
of gestation. There was no sign of toxic damage to the placentas as well as maternal and
fetal organs of the mice treated with 20- and 50-nm gold nanoparticles. ICP-MS analysis
demonstrated significant amounts of gold deposited in the maternal livers and placentas,
but no detectable level of gold in the fetal organs. However, electron microscopy
demonstrated an increase of endocytic vesicles in the cytoplasm of syncytiotrophoblasts
and fetal endothelial cells in the maternal–fetal barrier of mice treated with gold
nanoparticles. Clathrin immunohistochemistry and immunoblotting showed increased
immunoreactivity of clathrin protein in the placental tissues of mice treated with 20- and
50-nm gold nanoparticles; clathrin immunopositivity was observed in syncytiotrophoblasts
and fetal endothelial cells. In contrast, caveolin-1 immunopositivity was observed
exclusively in the fetal endothelium. These findings suggested that intravenous
administration of gold nanoparticles may upregulate clathrin- and caveolin-mediated
endocytosis at the maternal–fetal barrier in mouse placenta.